Hyperuricemia – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Hyperuricemia Emerging Therapy and TPP Insights

Thelansis’s “Hyperuricemia Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Hyperuricemia Overview

Hyperuricemia is an elevated serum urate level, most often due to reduced renal excretion or excess production. It is often asymptomatic; persistent supersaturation can form monosodium urate crystals, causing gout, tophi and joint damage. Uric acid stones may also occur. Management depends on symptoms: asymptomatic hyperuricemia is generally not treated routinely under major US and kidney guidelines. For gout requiring urate-lowering therapy, allopurinol is preferred first-line; febuxostat or selected uricosurics are alternatives. Pegloticase is reserved for severe gout refractory to conventional treatment. Therapy is titrated to keep serum urate below 6 mg/dL, with flare prophylaxis when starting. New approaches include selective URAT1 inhibitors such as dotinurad and investigational pozdeutinurad, plus strategies to reduce uricase immunogenicity. Cardiovascular and kidney risks are associated with hyperuricemia, but routine urate lowering has not been shown to prevent these outcomes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)